The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Dazublys trastuzumab BiosimilarAdditional monitoring | CuraTeQ Biologics (Malta) Limited | Breast Neoplasms; Stomach Neoplasms | 🇪🇺 EU 2025-06-30 | Order → |
| Evfraxy denosumab BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2025-06-30 | Order → |
| Oczyesa octreotide | Camurus AB | Acromegaly | 🇪🇺 EU 2025-06-30 | Order → |
| Ziihera zanidatamab OrphanConditionalAdditional monitoring | Jazz Pharmaceuticals Ireland Limited | Biliary Tract Neoplasms | 🇪🇺 EU 2025-06-27 | Order → |
| Denbrayce denosumab BiosimilarAdditional monitoring | Mabxience Research SL | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-06-26 | Order → |
| Enwylma denosumab BiosimilarAdditional monitoring | Zentiva k.s. | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-06-26 | Order → |
| Izamby denosumab BiosimilarAdditional monitoring | Mabxience Research SL | Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2025-06-26 | Order → |
| Zadenvi denosumab BiosimilarAdditional monitoring | Zentiva k.s. | Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2025-06-26 | Order → |
| Vevzuo denosumab BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-06-25 | Order → |
| Junod denosumab BiosimilarAdditional monitoring | Gedeon Richter Plc. | Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2025-06-23 | Order → |
| Yaxwer denosumab BiosimilarAdditional monitoring | Gedeon Richter Plc. | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-06-23 | Order → |
| Sephience sepiapterin Orphan | PTC Therapeutics International Limited | Phenylketonurias | 🇪🇺 EU 2025-06-19 | Order → |
| Tepezza teprotumumab Additional monitoring | Amgen Europe B.V. | Graves Ophthalmopathy | 🇪🇺 EU 2025-06-19 | Order → |
| Xoanacyl ferric citrate coordination complex Additional monitoring | Averoa | Iron Deficiencies; Renal Insufficiency, Chronic; Hyperphosphatemia | 🇪🇺 EU 2025-06-11 | Order → |
| Duvyzat givinostat OrphanConditionalAdditional monitoring | Italfarmaco S.p.A. | Muscular Dystrophy, Duchenne | 🇪🇺 EU 2025-06-06 | Order → |
| Qoyvolma ustekinumab BiosimilarAdditional monitoring | Celltrion Healthcare Hungary Kft. | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | 🇪🇺 EU 2025-06-02 | Order → |
| Ryjunea atropine sulfate | Santen Oy | Myopia | 🇪🇺 EU 2025-06-02 | Order → |
| Jubereq denosumab BiosimilarAdditional monitoring | Accord Healthcare S.L.U. | Neoplasms, Bone Tissue; Giant Cell Tumor of Bone | 🇪🇺 EU 2025-05-26 | Order → |
| Osvyrti denosumab BiosimilarAdditional monitoring | Accord Healthcare S.L.U. | Bone Resorption; Osteoporosis; Osteoporosis, Postmenopausal | 🇪🇺 EU 2025-05-26 | Order → |
| Deqsiga human normal immunoglobulin Additional monitoring | Takeda Manufacturing Austria AG | Immunologic Deficiency Syndromes; Purpura, Thrombocytopenic, Idiopathic; Guillain-Barre Syndrome; Mucocutaneous Lymph Node Syndrome; Polyradiculoneuropathy, Chr | 🇪🇺 EU 2025-05-02 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.